valproic acid has been researched along with Neoplasms in 74 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cancer incidence of bipolar disorder patients treated with VPA was no significant difference than treated with lithium and other anticonvulsants." | 7.88 | Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD). ( Hsieh, TC; Lin, CC; Wu, LS, 2018) |
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| " In this study, we investigated the mechanism of how valproic acid (VPA) interferes with the carcinogenesis of PAHs protect normal tissues via the regulation of macrophages' function." | 4.12 | Valproic acid counteracts polycyclic aromatic hydrocarbons (PAHs)-induced tumorigenic effects by regulating the polarization of macrophages. ( Cai, Z; Chu, G; Dong, C; Feng, Z; Jia, B; Lim, D; Peng, J; Zhang, F; Zhang, Y, 2022) |
| "The cancer incidence of bipolar disorder patients treated with VPA was no significant difference than treated with lithium and other anticonvulsants." | 3.88 | Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD). ( Hsieh, TC; Lin, CC; Wu, LS, 2018) |
| "Valproic acid (VPA) has been used for epilepsy treatment since the 1970s." | 3.76 | Valproic acid in the complex therapy of malignant tumors. ( Eckschlager, T; Hrabeta, J; Hrebackova, J, 2010) |
| " The effects of HDAC inhibitors in promoting the healing of wounds caused by radiation and in decreasing later skin fibrosis and tumorigenesis were correlated with suppression of the aberrant expression of radiation-induced transforming growth factor beta and tumor necrosis factor alpha." | 3.72 | Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. ( Chung, YL; Wang, AJ; Yao, LF, 2004) |
| "Twenty-six patients with advanced cancer (14 men/12 women), median age of 56 years (range 38-70 years), and a median number of two prior therapies (range 0-12) were enrolled." | 2.80 | Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. ( Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ, 2015) |
| " Sequential treatment with azacitidine and valproic acid (VPA) in combination with carboplatin may overcome resistance to platinum-based therapy, and we conducted a phase I trial to assess safety, maximum tolerated dose (MTD), and clinical correlates." | 2.78 | Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. ( Bustinza-Linares, E; Falchook, GS; Fu, S; Hong, DS; Hu, W; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Sood, AK; Wheler, JJ, 2013) |
| " Blood and tumor tissue were collected for determination of serum valproic acid concentration and evaluation of pharmacodynamic effects by immunofluorescence cytochemistry and immunohistochemistry." | 2.75 | Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. ( Gustafson, DL; Thamm, DH; Wittenburg, LA, 2010) |
| "Valproic acid is a clinically relevant HDAC inhibitor, and PBMCs may serve as a surrogate for tumor histone acetylation in solid tumor malignancies." | 2.74 | Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. ( Bicaku, E; Centeno, B; Daud, A; Kim, J; Lacevic, M; Marchion, D; Minton, S; Munster, P; Neuger, A; Sullivan, D, 2009) |
| "Valproic acid is a histone deacetylase inhibitor." | 2.73 | Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. ( Alexander, S; Braiteh, F; Garcia-Manero, G; Hong, D; Johnson, MM; Kurzrock, R; Silva, Lde P; Soriano, AO; Wolff, J; Yang, H, 2008) |
| "Phenytoin dosing is critical in cancer patients as to decreased absorption secondary to chemotherapy-induced gastrointestinal toxicity, increased phenytoin metabolism in the liver secondary to chemotherapy, extreme patient profile that falls outside the predicted pharmacokinetic population, frequent hypoalbuminaemia and polydrug treatment." | 2.72 | Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. ( Beijnen, JH; Boogerd, W; Huitema, AD; Joerger, M; Schellens, JH; van der Sande, JJ, 2006) |
| "Pain was assessed using a pain scale based on the Brief Pain Inventory at days 0, 8 and 15." | 2.70 | A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. ( A'Hern, R; Broadley, K; Gwilliam, B; Hardy, JR; Ling, J; Rees, EA, 2001) |
| "In the past decade, its anticancer effects were discovered." | 2.61 | El ácido valproico como agente sensibilizador al tratamiento anticáncer. ( Correa-Basurto, J; Luna-Palencia, GR; Vásquez-Moctezuma, I, 2019) |
| "Valproic acid (VPA) is an anti-epileptic drug (AED) which is currently being investigated for its potential application in the treatment of several types of cancers, including solid and non-solid tumor." | 2.58 | Teratology of valproic acid: an updated review of the possible mediating mechanisms. ( Ponzano, A; Tiboni, GM, 2018) |
| " Hydralazine-valproate is safe when used alone or in combination with chemotherapy or chemoradiation." | 2.50 | Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. ( Cetina, L; Chavez-Blanco, A; Coronel, J; Dueñas-Gonzalez, A; González-Fierro, A; Taja-Chayeb, L, 2014) |
| "Valproic acid (VPA) has been used in clinical practice as an anticonvulsant for more than four decades." | 2.49 | New perspectives of valproic acid in clinical practice. ( Činčárová, L; Fajkus, J; Zdráhal, Z, 2013) |
| "In 1999, the first clinical anti-cancer trial using VPA was initiated." | 2.44 | Valproic acid as anti-cancer drug. ( Cinatl, J; Doerr, HW; Michaelis, M, 2007) |
| "For some malignant cancers even combined surgical, radiotherapeutic and chemotherapeutic approaches are not curative, indeed, in certain tumour types even a modest survival benefit is difficult to achieve." | 2.44 | Approaches to mitochondrially mediated cancer therapy. ( Murray, SA; Parker, K; Pilkington, GJ, 2008) |
| "Among many anticancer drugs collectively named "targeted or molecular therapies" epigenetic drugs are clearly promising." | 2.44 | Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. ( Candelaria, M; de la Cruz-Hernandez, E; Duenas-Gonzalez, A; Herrera, LA; Perez-Cardenas, E; Perez-Plascencia, C, 2008) |
| "A corresponding cancer-suppressive effect has not been studied in human epidemiological studies, though there are now preliminary reports of the use of valproate in human haematological and solid tumours." | 2.43 | Cancer risk in people with epilepsy: the role of antiepileptic drugs. ( Driever, PH; Sander, JW; Singh, G, 2005) |
| "Pro-drug activation, a modality of cancer therapy leads to Ganciclovir triphosphate (GCV-TP) incorporation into newly synthesized DNA resulting in cell death." | 1.62 | Modifying gap junction communication in cancer therapy. ( Jain, V; Kamble, V; Nanda, A; Patel, H; Warawdekar, UM, 2021) |
| "Background : Cancer stem cell properties are highly relevant to the biology of treatment-resistant cancers." | 1.56 | Effect of epigenetic modulation on cancer sphere. ( Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, Y; Shimada, M; Utsunomiya, T; Yamada, S, 2020) |
| "Single‑agent targeted cancer therapy frequently fails due to acquired drug resistance." | 1.51 | Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid‑induced epithelial‑mesenchymal transition and stemness in HeLa, 5637 and SCC‑15 cells. ( Chen, Y; Cui, G; Li, M; Meng, F; Yu, Z; Zhang, Y, 2019) |
| "The anticancer effects of histone deacetylase inhibitors (HDACi) vary between patients, and their molecular mechanisms remain poorly understood." | 1.48 | HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors. ( Fujii, K; Idogawa, M; Iwatsuki, K; Jimura, N; Kanekura, T; Kondo, T; Suzuki, N, 2018) |
| "Valproic acid treatment similarly increased the GM3 level and reduced phosphorylation of EGFR in U87MG glioma cells and inhibited their proliferation." | 1.43 | Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth. ( Kawashima, N; Nakayama, KI; Nishimiya, Y; Takahata, S, 2016) |
| "Valproic acid is an inhibitor of class I histone deacetylases." | 1.40 | Could valproic acid be an effective anticancer agent? The evidence so far. ( Brandes, JC; Brodie, SA, 2014) |
| "It is further posited that, in autism, the drugs act as "triggers" that disturb the pro-proliferative fetal milieu using the same, mainly epigenetic, mechanisms that they demonstrate in rapidly proliferating cancer cells." | 1.40 | Autism's cancer connection: the anti-proliferation hypothesis and why it may matter. ( Ward, CS, 2014) |
| "To investigate their potential use as cancer testis antigen (CTA) vaccines, we studied the expression of 12 cancer testis (CT) genes in 20 LCL by RT-PCR." | 1.39 | EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. ( Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C, 2013) |
| "Hazard ratios (HRs) for all cancers and individual cancers between the exposed and unexposed groups, with smoking and alcohol consumption and age as covariates, were calculated using the Cox proportional hazards method." | 1.38 | Cancer risk in people with epilepsy using valproate-sodium. ( Bell, GS; Driever, PH; Sander, JW; Singh, G, 2012) |
| "Both BuNa and VaNa inhibited cancer cell proliferation in a time--and dose-dependent fashion." | 1.38 | [Possibilities of epigenetic anti-tumor therapy in in-vitro models]. ( Bondarev, GN; Filatov, MV; Ibatulin, FM; Kovalëv, RA; Stam, TA, 2012) |
| "Prostate, colon, breast and cervical cancer cell lines were analyzed for the expression of MICA and MICB at the mRNA and protein levels by RT-PCR, Western blot, flow cytometry and ELISA." | 1.37 | Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. ( Alatorre, B; Chacón-Salinas, R; Chávez-Blanco, A; Contreras-Paredes, A; De la Cruz-Hernández, E; Domínguez, GI; Dueñas-González, A; Pérez-Cárdenas, E; Rodríguez-Cortez, O; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE, 2011) |
| "A number of drugs developed against cancer-specific molecular targets have been shown to offer survival benefits alone or in combination with standard treatments, especially for those cases in which tumor pathogenesis is dominated by a single molecular abnormality." | 1.36 | p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. ( Amstutz, RA; Hecker, RM; Niggli, FK; Schäfer, BW; Wachtel, M; Walter, D, 2010) |
| "Sensitivity of cancer cells to the cytotoxic effects of topoisomerase II targeting agents is thought to depend on the expression of the topoisomerase IIalpha isoform, and drug resistance is often associated with loss or mutation of topoisomerase IIalpha." | 1.33 | Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. ( Bicaku, E; Daud, AI; Marchion, DC; Munster, PN; Sullivan, DM; Turner, JG, 2005) |
| "Treating cultured thoracic cancer cells with VA (0." | 1.33 | Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. ( Baras, A; Chua, A; Maxhimer, JB; Nguyen, DM; Schrump, DS; Shamimi-Noori, S; Yeow, WS; Ziauddin, MF, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (39.19) | 29.6817 |
| 2010's | 34 (45.95) | 24.3611 |
| 2020's | 11 (14.86) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Zhang, Y | 3 |
| Lim, D | 1 |
| Cai, Z | 1 |
| Peng, J | 1 |
| Jia, B | 1 |
| Chu, G | 1 |
| Zhang, F | 1 |
| Dong, C | 1 |
| Feng, Z | 1 |
| Du, S | 1 |
| Wang, X | 1 |
| Hu, Y | 1 |
| Zhang, S | 1 |
| Wang, D | 1 |
| Zhang, Q | 1 |
| Liu, S | 1 |
| Luna-Palencia, GR | 1 |
| Correa-Basurto, J | 2 |
| Vásquez-Moctezuma, I | 1 |
| Adeshakin, AO | 1 |
| Yan, D | 1 |
| Zhang, M | 1 |
| Wang, L | 1 |
| Adeshakin, FO | 1 |
| Liu, W | 1 |
| Wan, X | 1 |
| Kiweler, N | 1 |
| Wünsch, D | 1 |
| Wirth, M | 1 |
| Mahendrarajah, N | 1 |
| Schneider, G | 1 |
| Stauber, RH | 1 |
| Brenner, W | 1 |
| Butter, F | 1 |
| Krämer, OH | 1 |
| Lipska, K | 1 |
| Gumieniczek, A | 1 |
| Filip, AA | 1 |
| Xie, Z | 2 |
| Ikegami, T | 1 |
| Ago, Y | 2 |
| Okada, N | 2 |
| Tachibana, M | 2 |
| Iwahashi, S | 1 |
| Shimada, M | 1 |
| Morine, Y | 1 |
| Imura, S | 1 |
| Ikemoto, T | 1 |
| Saito, Y | 1 |
| Yamada, S | 1 |
| Utsunomiya, T | 1 |
| Yerlikaya, A | 1 |
| Kanbur, E | 1 |
| Stanley, BA | 1 |
| Tümer, E | 1 |
| Warawdekar, UM | 1 |
| Jain, V | 1 |
| Patel, H | 1 |
| Nanda, A | 1 |
| Kamble, V | 1 |
| Okoye, I | 1 |
| Xu, L | 1 |
| Motamedi, M | 1 |
| Parashar, P | 1 |
| Walker, JW | 1 |
| Elahi, S | 1 |
| Park, M | 1 |
| Kwon, J | 1 |
| Youk, H | 1 |
| Shin, US | 1 |
| Han, YH | 1 |
| Kim, Y | 1 |
| Ponzano, A | 1 |
| Tiboni, GM | 1 |
| Péraudeau, E | 1 |
| Cronier, L | 1 |
| Monvoisin, A | 1 |
| Poinot, P | 1 |
| Mergault, C | 1 |
| Guilhot, F | 1 |
| Tranoy-Opalinski, I | 1 |
| Renoux, B | 1 |
| Papot, S | 1 |
| Clarhaut, J | 1 |
| Booth, L | 1 |
| Roberts, JL | 1 |
| Poklepovic, A | 1 |
| Kirkwood, J | 1 |
| Sander, C | 1 |
| Avogadri-Connors, F | 1 |
| Cutler, RE | 1 |
| Lalani, AS | 1 |
| Dent, P | 1 |
| Kurosawa, Y | 1 |
| Furugen, A | 1 |
| Nishimura, A | 1 |
| Narumi, K | 1 |
| Kobayashi, M | 1 |
| Iseki, K | 1 |
| Fujii, K | 1 |
| Suzuki, N | 1 |
| Jimura, N | 1 |
| Idogawa, M | 1 |
| Kondo, T | 1 |
| Iwatsuki, K | 1 |
| Kanekura, T | 1 |
| Lin, CC | 1 |
| Hsieh, TC | 1 |
| Wu, LS | 1 |
| Shah, RR | 1 |
| Stonier, PD | 1 |
| Li, M | 1 |
| Meng, F | 1 |
| Yu, Z | 1 |
| Chen, Y | 1 |
| Cui, G | 1 |
| Soria-Castro, R | 1 |
| Schcolnik-Cabrera, A | 1 |
| Rodríguez-López, G | 1 |
| Campillo-Navarro, M | 1 |
| Puebla-Osorio, N | 1 |
| Estrada-Parra, S | 1 |
| Estrada-García, I | 1 |
| Chacón-Salinas, R | 2 |
| Chávez-Blanco, AD | 1 |
| Kovalëv, RA | 1 |
| Stam, TA | 1 |
| Ibatulin, FM | 1 |
| Bondarev, GN | 1 |
| Filatov, MV | 1 |
| Neumann, F | 1 |
| Kaddu-Mulindwa, D | 1 |
| Widmann, T | 1 |
| Preuss, KD | 1 |
| Held, G | 1 |
| Zwick, C | 1 |
| Roemer, K | 1 |
| Pfreundschuh, M | 1 |
| Kubuschok, B | 1 |
| Falchook, GS | 3 |
| Fu, S | 3 |
| Naing, A | 3 |
| Hong, DS | 3 |
| Hu, W | 1 |
| Moulder, S | 1 |
| Wheler, JJ | 3 |
| Sood, AK | 1 |
| Bustinza-Linares, E | 1 |
| Parkhurst, KL | 1 |
| Kurzrock, R | 4 |
| Činčárová, L | 1 |
| Zdráhal, Z | 1 |
| Fajkus, J | 1 |
| Ward, CS | 1 |
| Janku, F | 1 |
| Jackson, TL | 1 |
| Tsimberidou, AM | 2 |
| Moulder, SL | 1 |
| Yang, H | 2 |
| Piha-Paul, SA | 1 |
| Atkins, JT | 1 |
| Garcia-Manero, G | 2 |
| Arbez, J | 1 |
| Lamarthée, B | 1 |
| Gaugler, B | 1 |
| Saas, P | 1 |
| Samuni, Y | 1 |
| Wink, DA | 1 |
| Krishna, MC | 1 |
| Mitchell, JB | 1 |
| Goldstein, S | 1 |
| Brodie, SA | 1 |
| Brandes, JC | 1 |
| Dueñas-Gonzalez, A | 4 |
| Coronel, J | 1 |
| Cetina, L | 2 |
| González-Fierro, A | 2 |
| Chavez-Blanco, A | 3 |
| Taja-Chayeb, L | 3 |
| Bilen, MA | 1 |
| Ng, CS | 1 |
| Abdelrahim, M | 1 |
| Erguvan-Dogan, B | 1 |
| Adachi, T | 1 |
| Kano, A | 1 |
| Nonomura, S | 1 |
| Kamiya, T | 1 |
| Hara, H | 1 |
| Kawashima, N | 1 |
| Nishimiya, Y | 1 |
| Takahata, S | 1 |
| Nakayama, KI | 1 |
| Martínez-Pacheco, H | 1 |
| Ramírez-Galicia, G | 1 |
| Vergara-Arias, M | 1 |
| Gertsch, J | 1 |
| Fragoso-Vazquez, JM | 1 |
| Mendez-Luna, D | 1 |
| Abujamra, AL | 1 |
| Cristina, CL | 1 |
| Cecilia, RM | 1 |
| Mendoza-Lujambio, I | 1 |
| Rodriguez-Menendez, V | 1 |
| Tremolizzo, L | 1 |
| Cavaletti, G | 1 |
| Braiteh, F | 1 |
| Soriano, AO | 1 |
| Hong, D | 1 |
| Johnson, MM | 1 |
| Silva, Lde P | 1 |
| Alexander, S | 1 |
| Wolff, J | 1 |
| Zhang, C | 1 |
| Wang, Y | 1 |
| Zhou, Z | 1 |
| Zhang, J | 1 |
| Tian, Z | 1 |
| Munster, P | 2 |
| Marchion, D | 2 |
| Bicaku, E | 3 |
| Lacevic, M | 1 |
| Kim, J | 1 |
| Centeno, B | 1 |
| Daud, A | 2 |
| Neuger, A | 1 |
| Minton, S | 2 |
| Sullivan, D | 2 |
| Hallas, J | 1 |
| Friis, S | 1 |
| Bjerrum, L | 1 |
| Støvring, H | 1 |
| Narverud, SF | 1 |
| Heyerdahl, T | 1 |
| Grønbaek, K | 1 |
| Andersen, M | 1 |
| Wang, XX | 1 |
| Fu, L | 1 |
| Häcker, S | 1 |
| Dittrich, A | 1 |
| Mohr, A | 1 |
| Schweitzer, T | 1 |
| Rutkowski, S | 1 |
| Krauss, J | 1 |
| Debatin, KM | 1 |
| Fulda, S | 1 |
| Hajji, N | 1 |
| Wallenborg, K | 1 |
| Vlachos, P | 1 |
| Füllgrabe, J | 1 |
| Hermanson, O | 1 |
| Joseph, B | 1 |
| David, KA | 1 |
| Mongan, NP | 1 |
| Smith, C | 1 |
| Gudas, LJ | 1 |
| Nanus, DM | 1 |
| Hrebackova, J | 1 |
| Hrabeta, J | 1 |
| Eckschlager, T | 1 |
| Hecker, RM | 1 |
| Amstutz, RA | 1 |
| Wachtel, M | 1 |
| Walter, D | 1 |
| Niggli, FK | 1 |
| Schäfer, BW | 1 |
| Wittenburg, LA | 1 |
| Gustafson, DL | 1 |
| Thamm, DH | 1 |
| De la Cruz-Hernández, E | 3 |
| Domínguez, GI | 1 |
| Rodríguez-Cortez, O | 1 |
| Alatorre, B | 1 |
| Pérez-Cárdenas, E | 3 |
| Trejo-Becerril, C | 2 |
| Trujillo, JE | 1 |
| Contreras-Paredes, A | 1 |
| Singh, G | 2 |
| Bell, GS | 1 |
| Driever, PH | 3 |
| Sander, JW | 2 |
| Yang, J | 1 |
| Sun, X | 1 |
| Mao, W | 1 |
| Sui, M | 1 |
| Tang, J | 1 |
| Shen, Y | 1 |
| Coulter, DW | 1 |
| Walko, C | 1 |
| Patel, J | 1 |
| Moats-Staats, BM | 1 |
| McFadden, A | 1 |
| Smith, SV | 1 |
| Khan, WA | 1 |
| Bridges, AS | 1 |
| Deal, AM | 1 |
| Oesterheld, J | 1 |
| Davis, IJ | 1 |
| Blatt, J | 1 |
| Chung, YL | 1 |
| Wang, AJ | 1 |
| Yao, LF | 1 |
| Göttlicher, M | 2 |
| Blaheta, RA | 1 |
| Michaelis, M | 2 |
| Cinatl, J | 2 |
| Stepulak, A | 1 |
| Stryjecka-Zimmer, M | 1 |
| Kupisz, K | 1 |
| Polberg, K | 1 |
| Liu, AL | 1 |
| Long, J | 1 |
| Wang, N | 1 |
| Du, GH | 1 |
| Marchion, DC | 1 |
| Turner, JG | 1 |
| Daud, AI | 1 |
| Sullivan, DM | 1 |
| Munster, PN | 1 |
| Yeow, WS | 1 |
| Ziauddin, MF | 1 |
| Maxhimer, JB | 1 |
| Shamimi-Noori, S | 1 |
| Baras, A | 1 |
| Chua, A | 1 |
| Schrump, DS | 1 |
| Nguyen, DM | 1 |
| Joerger, M | 1 |
| Huitema, AD | 1 |
| Boogerd, W | 1 |
| van der Sande, JJ | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Mack, GS | 1 |
| Kostrouchová, M | 2 |
| Kostrouch, Z | 1 |
| Carraway, HE | 1 |
| Gore, SD | 1 |
| Schmitt, M | 1 |
| Lee, JH | 1 |
| DeConti, R | 1 |
| Simon, G | 1 |
| Fishman, M | 1 |
| Garrett, C | 1 |
| Chiappori, A | 1 |
| Lush, R | 1 |
| Atmaca, A | 1 |
| Al-Batran, SE | 1 |
| Maurer, A | 1 |
| Neumann, A | 1 |
| Heinzel, T | 1 |
| Hentsch, B | 1 |
| Schwarz, SE | 1 |
| Hövelmann, S | 1 |
| Knuth, A | 1 |
| Jäger, E | 1 |
| Candelaria, M | 2 |
| Gallardo-Rincón, D | 1 |
| Arce, C | 1 |
| Aguilar-Ponce, JL | 1 |
| Arrieta, O | 1 |
| Camargo, MF | 1 |
| Pérez-Plasencia, C | 1 |
| Wegman-Ostrosky, T | 1 |
| Revilla-Vazquez, A | 1 |
| Doerr, HW | 1 |
| Pilkington, GJ | 1 |
| Parker, K | 1 |
| Murray, SA | 1 |
| Perez-Plascencia, C | 1 |
| Herrera, LA | 1 |
| Hardy, JR | 1 |
| Rees, EA | 1 |
| Gwilliam, B | 1 |
| Ling, J | 1 |
| Broadley, K | 1 |
| A'Hern, R | 1 |
| Davies, AN | 1 |
| Sinnott, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Sequential Azacitidine and Valproic Acid Plus Carboplatin in the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer[NCT00529022] | Phase 1 | 36 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors[NCT00404508] | Phase 2 | 15 participants | Interventional | 2005-09-30 | Completed | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for valproic acid and Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
El ácido valproico como agente sensibilizador al tratamiento anticáncer.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Ne | 2019 |
El ácido valproico como agente sensibilizador al tratamiento anticáncer.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Ne | 2019 |
Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Epigene | 2020 |
Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Epigene | 2020 |
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Topics: Acetylation; Boron Compounds; Bortezomib; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis | 2021 |
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Topics: Acetylation; Boron Compounds; Bortezomib; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis | 2021 |
Teratology of valproic acid: an updated review of the possible mediating mechanisms.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Antineoplastic Agents; Female; Humans; Neopla | 2018 |
Teratology of valproic acid: an updated review of the possible mediating mechanisms.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Antineoplastic Agents; Female; Humans; Neopla | 2018 |
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
Topics: Antineoplastic Agents; Astemizole; Cost-Benefit Analysis; Drug Repositioning; Genomics; Humans; Metf | 2019 |
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
Topics: Antineoplastic Agents; Astemizole; Cost-Benefit Analysis; Drug Repositioning; Genomics; Humans; Metf | 2019 |
Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells.
Topics: Adaptive Immunity; Animals; Apoptosis; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Prol | 2019 |
Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells.
Topics: Adaptive Immunity; Animals; Apoptosis; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Prol | 2019 |
New perspectives of valproic acid in clinical practice.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Neoplasms; | 2013 |
New perspectives of valproic acid in clinical practice.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Neoplasms; | 2013 |
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; DNA | 2014 |
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; DNA | 2014 |
Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?
Topics: Animals; Antineoplastic Agents; Cisplatin; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetyla | 2008 |
Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?
Topics: Animals; Antineoplastic Agents; Cisplatin; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetyla | 2008 |
[Recent advances in DNA demethylation in tumor therapy].
Topics: Animals; Cytidine; DNA Methylation; DNA Modification Methylases; Gene Knockout Techniques; Histone A | 2009 |
[Recent advances in DNA demethylation in tumor therapy].
Topics: Animals; Cytidine; DNA Methylation; DNA Modification Methylases; Gene Knockout Techniques; Histone A | 2009 |
Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.
Topics: Acetylation; Anticonvulsants; Chromatin; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; | 2004 |
Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.
Topics: Acetylation; Anticonvulsants; Chromatin; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; | 2004 |
Cancer risk in people with epilepsy: the role of antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Neoplasms; Phenobarbital; Phenytoin; Rats | 2005 |
Cancer risk in people with epilepsy: the role of antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Neoplasms; Phenobarbital; Phenytoin; Rats | 2005 |
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Differentiation; Cytos | 2005 |
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Differentiation; Cytos | 2005 |
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
Topics: Animals; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Ac | 2005 |
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
Topics: Animals; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Ac | 2005 |
[A new target of cancer therapy: advances in the study of histone deacetylase].
Topics: Acetylation; Animals; Apoptosis; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Histone Acety | 2005 |
[A new target of cancer therapy: advances in the study of histone deacetylase].
Topics: Acetylation; Animals; Apoptosis; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Histone Acety | 2005 |
Valproic acid, a molecular lead to multiple regulatory pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Gene Expression Regu | 2007 |
Valproic acid, a molecular lead to multiple regulatory pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Gene Expression Regu | 2007 |
Valproic acid as anti-cancer drug.
Topics: Animals; Anticonvulsants; Antimanic Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; | 2007 |
Valproic acid as anti-cancer drug.
Topics: Animals; Anticonvulsants; Antimanic Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; | 2007 |
Approaches to mitochondrially mediated cancer therapy.
Topics: Animals; Dexamethasone; Gangliosides; Humans; Mitochondria; Neoplasms; Neoplastic Stem Cells; Valpro | 2008 |
Approaches to mitochondrially mediated cancer therapy.
Topics: Animals; Dexamethasone; Gangliosides; Humans; Mitochondria; Neoplasms; Neoplastic Stem Cells; Valpro | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Neop | 2008 |
13 trials available for valproic acid and Neoplasms
| Article | Year |
|---|---|
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aza | 2013 |
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aza | 2013 |
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2014 |
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2014 |
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L | 2015 |
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L | 2015 |
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Cohort | 2008 |
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Cohort | 2008 |
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Enzy | 2009 |
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Enzy | 2009 |
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitor | 2010 |
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitor | 2010 |
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liqu | 2010 |
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liqu | 2010 |
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Diphenhydramine | 2013 |
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Diphenhydramine | 2013 |
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Algorithms; Analysis of Variance; Antineoplast | 2006 |
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Algorithms; Analysis of Variance; Antineoplast | 2006 |
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; | 2007 |
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; | 2007 |
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Topics: Adult; Antineoplastic Agents; Enzyme Inhibitors; Female; Histone Deacetylase 2; Histone Deacetylase | 2007 |
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Topics: Adult; Antineoplastic Agents; Enzyme Inhibitors; Female; Histone Deacetylase 2; Histone Deacetylase | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain.
Topics: Adult; Aged; Anticonvulsants; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; | 2001 |
A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain.
Topics: Adult; Aged; Anticonvulsants; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; | 2001 |
41 other studies available for valproic acid and Neoplasms
| Article | Year |
|---|---|
Valproic acid counteracts polycyclic aromatic hydrocarbons (PAHs)-induced tumorigenic effects by regulating the polarization of macrophages.
Topics: Carcinogenesis; Carcinogens; CD8-Positive T-Lymphocytes; Cytokines; Endothelial Cells; Humans; Macro | 2022 |
Valproic acid counteracts polycyclic aromatic hydrocarbons (PAHs)-induced tumorigenic effects by regulating the polarization of macrophages.
Topics: Carcinogenesis; Carcinogens; CD8-Positive T-Lymphocytes; Cytokines; Endothelial Cells; Humans; Macro | 2022 |
Valproic acid regulates MIEF1 through MST2-HIPPO to suppress breast cancer growth.
Topics: Animals; Apoptosis; Cell Line, Tumor; Membrane Potential, Mitochondrial; Mitochondrial Proteins; Neo | 2022 |
Valproic acid regulates MIEF1 through MST2-HIPPO to suppress breast cancer growth.
Topics: Animals; Apoptosis; Cell Line, Tumor; Membrane Potential, Mitochondrial; Mitochondrial Proteins; Neo | 2022 |
Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Topics: Animals; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Histone Deacetylase | 2020 |
Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Topics: Animals; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Histone Deacetylase | 2020 |
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Topics: Animals; Benzamides; Cell Plasticity; Cisplatin; DNA Repair; DNA Repair Enzymes; DNA-Binding Protein | 2020 |
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Topics: Animals; Benzamides; Cell Plasticity; Cisplatin; DNA Repair; DNA Repair Enzymes; DNA-Binding Protein | 2020 |
Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Topics: Animals; Humans; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Neoplasms; Receptors, C | 2020 |
Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Topics: Animals; Humans; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Neoplasms; Receptors, C | 2020 |
Effect of epigenetic modulation on cancer sphere.
Topics: DNA Methylation; Epithelial-Mesenchymal Transition; Hep G2 Cells; Histone Deacetylase Inhibitors; Hu | 2020 |
Effect of epigenetic modulation on cancer sphere.
Topics: DNA Methylation; Epithelial-Mesenchymal Transition; Hep G2 Cells; Histone Deacetylase Inhibitors; Hu | 2020 |
Modifying gap junction communication in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Communication; Cell Line, Tumor; Cell Membrane; Co | 2021 |
Modifying gap junction communication in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Communication; Cell Line, Tumor; Cell Membrane; Co | 2021 |
Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Ly | 2020 |
Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Ly | 2020 |
Valproic acid protects intestinal organoids against radiation via NOTCH signaling.
Topics: Animals; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasms; Organoids; Protective Agents; Radiation | 2021 |
Valproic acid protects intestinal organoids against radiation via NOTCH signaling.
Topics: Animals; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasms; Organoids; Protective Agents; Radiation | 2021 |
Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.
Topics: Animals; Cell Line; Dexamethasone; Female; Folate Receptor 1; Humans; Mice, Inbred BALB C; Molecular | 2018 |
Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.
Topics: Animals; Cell Line; Dexamethasone; Female; Folate Receptor 1; Humans; Mice, Inbred BALB C; Molecular | 2018 |
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy-Related Protein 5; Beclin-1; Cell Line, Tu | 2018 |
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy-Related Protein 5; Beclin-1; Cell Line, Tu | 2018 |
Evaluation of the effects of antiepileptic drugs on folic acid uptake by human placental choriocarcinoma cells.
Topics: Adult; Anticonvulsants; Cell Line, Tumor; Cell Survival; Choriocarcinoma; Female; Folate Receptor 1; | 2018 |
Evaluation of the effects of antiepileptic drugs on folic acid uptake by human placental choriocarcinoma cells.
Topics: Adult; Anticonvulsants; Cell Line, Tumor; Cell Survival; Choriocarcinoma; Female; Folate Receptor 1; | 2018 |
HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
Topics: Acetylation; Apoptosis; Benzhydryl Compounds; Drug Resistance, Neoplasm; Gene Expression Regulation, | 2018 |
HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
Topics: Acetylation; Apoptosis; Benzhydryl Compounds; Drug Resistance, Neoplasm; Gene Expression Regulation, | 2018 |
Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD).
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Lithi | 2018 |
Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD).
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Lithi | 2018 |
Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; B7-H1 Antigen; Cells, Cultured; Dose-Response Relat | 2018 |
Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; B7-H1 Antigen; Cells, Cultured; Dose-Response Relat | 2018 |
Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid‑induced epithelial‑mesenchymal transition and stemness in HeLa, 5637 and SCC‑15 cells.
Topics: Benzamides; Dioxoles; Diphenylamine; Drug Synergism; Epithelial-Mesenchymal Transition; HeLa Cells; | 2019 |
Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid‑induced epithelial‑mesenchymal transition and stemness in HeLa, 5637 and SCC‑15 cells.
Topics: Benzamides; Dioxoles; Diphenylamine; Drug Synergism; Epithelial-Mesenchymal Transition; HeLa Cells; | 2019 |
[Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyric Acid; Cell | 2012 |
[Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyric Acid; Cell | 2012 |
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Posit | 2013 |
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Posit | 2013 |
Autism's cancer connection: the anti-proliferation hypothesis and why it may matter.
Topics: Antineoplastic Agents; Autistic Disorder; Epigenetic Repression; Gene Expression Regulation, Neoplas | 2014 |
Autism's cancer connection: the anti-proliferation hypothesis and why it may matter.
Topics: Antineoplastic Agents; Autistic Disorder; Epigenetic Repression; Gene Expression Regulation, Neoplas | 2014 |
Histone deacetylase inhibitor valproic acid affects plasmacytoid dendritic cells phenotype and function.
Topics: Antigens, CD; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cells, Cultured; | 2014 |
Histone deacetylase inhibitor valproic acid affects plasmacytoid dendritic cells phenotype and function.
Topics: Antigens, CD; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cells, Cultured; | 2014 |
Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide.
Topics: Antioxidants; Cell Hypoxia; Cell Line, Tumor; Cyclic N-Oxides; Enzyme Inhibitors; G1 Phase Cell Cycl | 2014 |
Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide.
Topics: Antioxidants; Cell Hypoxia; Cell Line, Tumor; Cyclic N-Oxides; Enzyme Inhibitors; G1 Phase Cell Cycl | 2014 |
Could valproic acid be an effective anticancer agent? The evidence so far.
Topics: Antineoplastic Agents; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Hu | 2014 |
Could valproic acid be an effective anticancer agent? The evidence so far.
Topics: Antineoplastic Agents; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Hu | 2014 |
Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment.
Topics: A549 Cells; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Calcium; Cell Death; Cell Surv | 2016 |
Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment.
Topics: A549 Cells; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Calcium; Cell Death; Cell Surv | 2016 |
Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G(M3) Ganglioside; Gene Expression Regulation, | 2016 |
Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G(M3) Ganglioside; Gene Expression Regulation, | 2016 |
Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Ant | 2017 |
Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Ant | 2017 |
Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
Topics: Butyrates; Cell Line, Tumor; Cytotoxicity, Immunologic; DNA-Binding Proteins; Enzyme Inhibitors; Hea | 2009 |
Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
Topics: Butyrates; Cell Line, Tumor; Cytotoxicity, Immunologic; DNA-Binding Proteins; Enzyme Inhibitors; Hea | 2009 |
Cancer risk in long-term users of valproate: a population-based case-control study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Anticonvulsants; Case-Control Studies; Enzyme Inhi | 2009 |
Cancer risk in long-term users of valproate: a population-based case-control study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Anticonvulsants; Case-Control Studies; Enzyme Inhi | 2009 |
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Dru | 2009 |
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Dru | 2009 |
Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Topics: Acetylation; Animals; Cell Death; Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Resistance, Ne | 2010 |
Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Topics: Acetylation; Animals; Cell Death; Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Resistance, Ne | 2010 |
Valproic acid in the complex therapy of malignant tumors.
Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; | 2010 |
Valproic acid in the complex therapy of malignant tumors.
Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; | 2010 |
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2010 |
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2010 |
Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Histocompatibility Antigens Clas | 2011 |
Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Histocompatibility Antigens Clas | 2011 |
Cancer risk in people with epilepsy using valproate-sodium.
Topics: Adult; Causality; Comorbidity; Epilepsy; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Pr | 2012 |
Cancer risk in people with epilepsy using valproate-sodium.
Topics: Adult; Causality; Comorbidity; Epilepsy; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Pr | 2012 |
Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; HeLa Cells; His | 2012 |
Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; HeLa Cells; His | 2012 |
Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy.
Topics: Acetylation; Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor | 2004 |
Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy.
Topics: Acetylation; Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor | 2004 |
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Butyrates; Chromatin; DNA Topoisomerases, Type | 2005 |
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Butyrates; Chromatin; DNA Topoisomerases, Type | 2005 |
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; | 2006 |
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; | 2006 |
Epigenetic cancer therapy makes headway.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, G | 2006 |
Epigenetic cancer therapy makes headway.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, G | 2006 |
Addition of histone deacetylase inhibitors in combination therapy.
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Histone Deace | 2007 |
Addition of histone deacetylase inhibitors in combination therapy.
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Histone Deace | 2007 |
Re: Sodium valproate in cancer-related neuropathic pain.
Topics: Anticonvulsants; Humans; Neoplasms; Neuralgia; Valproic Acid | 2002 |
Re: Sodium valproate in cancer-related neuropathic pain.
Topics: Anticonvulsants; Humans; Neoplasms; Neuralgia; Valproic Acid | 2002 |
Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Humans; Multicenter Studies as Topic; Neoplasms; Ne | 2002 |
Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Humans; Multicenter Studies as Topic; Neoplasms; Ne | 2002 |